Copertina

Editorial: When and What to Ask—Capturing the Symptoms Experienced by Patients With PSC. Authors' Reply

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Natassia Tan, Christopher Zampogna, Amanda J. Nicoll
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Editorial: When and What to Ask—Capturing the Symptoms Experienced by Patients With PSC
di: Christopher L. Bowlus, et al.
Pubblicazione: (2025)

Editorial: PSC as an Independent Risk Factor for CRC Without IBD : Can Observed Epidemiological Trends Help Uncover Biological Mechanisms and Guide Surveillance Strategies?
di: Natassia Tan, et al.
Pubblicazione: (2025)

Editorial: The future of managing drug induced liver injury
di: Amanda Nicoll
Pubblicazione: (2024)

Editorial: Assessing the Prognosis of Patients With HBV and ACLF—Comorbidities Matter. Authors' Reply
di: Jiong Yu, et al.
Pubblicazione: (2024)

Editorial: When Yeast Turns Beast—Unmasking an Overlooked Threat in Alcohol‐Related Hepatitis. Authors' Reply
di: Vincent Mallet, et al.
Pubblicazione: (2025)

Editorial: Cephalosporin‐Induced Liver Injury—Interesting but Tricky. Authors' Reply
di: Raj Vuppalanchi, et al.
Pubblicazione: (2025)

Editorial: Food for Thought—Addressing the Nuances of Diet and Mood When Evaluating Dietary Intervention in IBS. Authors' Reply
di: Anthony O'Connor, et al.
Pubblicazione: (2024)

Editorial: Navigating the Beta‐Blocker Dilemma in Advanced Liver Cirrhosis—When Is the Right Time to Discontinue? Authors' Reply
di: Ting Wang, et al.
Pubblicazione: (2024)

Editorial: Getting to the Heart of the Matter in IBD—Authors' Reply
di: Ramin Ebrahimi, et al.
Pubblicazione: (2025)

Editorial: Optimal Treatment for Older Patients With Inflammatory Bowel Disease: How to Detect and Manage Frailty? Authors' Reply
di: A. B. Fons, et al.
Pubblicazione: (2026)

Editorial: Intestinal Ultrasound for the Assessment of Constipation—Out of the Shadows? Authors' Reply
di: Ryan M. Mathias, et al.
Pubblicazione: (2025)

Editorial: Clinical Impact of Lipid Profile Change After DAA Treatment in CHC Patients—Authors' Reply
di: Zahra Sarrafan‐Chaharsoughi, et al.
Pubblicazione: (2025)

Editorial: Association of Antibiotic Exposure With Microscopic Colitis—Authors' Reply
di: Máté Szilcz, et al.
Pubblicazione: (2025)

Editorial: Allostatic Load and Inflammatory Bowel Disease. Authors' Reply
di: Jianhui Zhao, et al.
Pubblicazione: (2024)

Editorial: To Stop or Not to Stop, Is It Still a Question? Authors' Reply
di: Jeongkuk Seo, et al.
Pubblicazione: (2024)

Editorial: Predicting Hepatocellular Cancer in Clinical Practice. Authors' Reply
di: Shuaibing Ying, et al.
Pubblicazione: (2026)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply
di: Virginia Solitano, et al.
Pubblicazione: (2024)

Editorial: M et ALD and Risk of Gastrointestinal Cancer—What Can We Learn From Japan? Authors' Reply
di: Nobuharu Tamaki, et al.
Pubblicazione: (2025)

Editorial: Can We Prevent Inflammatory Bowel Disease? Authors' Reply
di: Fai Fai Ho, et al.
Pubblicazione: (2025)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease: Authors' Reply
di: Suprabhat Giri, et al.
Pubblicazione: (2025)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol—Authors' Reply
di: Federica Tavaglione, et al.
Pubblicazione: (2025)

Editorial: Targeting Urgency in IBD —A Historical Divide. Authors' Reply
di: Parul Tandon, et al.
Pubblicazione: (2025)

Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease? Authors' Reply
di: Bharati Kochar, et al.
Pubblicazione: (2025)

Editorial: Seton Use in Perianal Fistulising Crohn's Disease. Authors' Reply
di: Jeffrey D McCurdy, et al.
Pubblicazione: (2025)

Editorial: The Role of Liver Biopsy in ANA Positive Subjects. Authors' Reply
di: David Mehdi Asgher Niazi, et al.
Pubblicazione: (2026)

Editorial: TIPS in the Era of Aging and Metabolic Comorbidity—Rethinking Risks and Rewards. Authors Reply
di: Michelle Spaan, et al.
Pubblicazione: (2026)

Editorial: UDCA Dosing in PBC—Between Guideline Adherence and Clinical Reality: Authors' Reply
di: Ellen Werner, et al.
Pubblicazione: (2026)

Editorial: Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab for Hepatocellular Carcinoma—Don't Ignore the Risk Factors! Authors' Reply
di: Jonggi Choi
Pubblicazione: (2025)

Editorial: Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients With Metabolic Dysfunction—Do Existing Scores Clear the Bar? Authors' Reply
di: Lesley A. Patmore, et al.
Pubblicazione: (2025)

Editorial: The Devil Is in the Detail—Interpreting the Findings of Network Meta‐Analyses. Authors' Reply
di: Mohammad Shehab, et al.
Pubblicazione: (2025)

Editorial: Resecting Assumptions—Do Proctocolectomy Guidelines Hold Up? Author's Reply
di: Erik Lundqvist, et al.
Pubblicazione: (2025)

Editorial: Redefining Decompensation in Cirrhosis—More Than an Academic Playground? Authors' Reply
di: Lucie Simonis, et al.
Pubblicazione: (2025)

Editorial: Genotyping for Hepatocellular Carcinoma Risk Stratification in the General Population. Authors' Reply
di: Daniel Q. Huang, et al.
Pubblicazione: (2026)

Editorial: Diabetes Management in Cirrhosis—The Window of Opportunity Before Decompensation. Authors' Reply
di: Mary Yue Wang, et al.
Pubblicazione: (2026)

Editorial: Ulcerative Colitis Management in the Biologic Era–Data From the English Healthcare Databases. Authors' Reply
di: J. Couch, et al.
Pubblicazione: (2025)

Editorial: Efficacy of Pharmacological Compared With Dietary Therapy for Patients With Irritable Bowel Syndrome—It Is Nice to Have a Choice. Authors' Reply
di: Kee Huat Chuah, et al.
Pubblicazione: (2025)

Editorial: Evaluating the Prevalence of Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinaemia—Authors' Reply
di: Maral Amangurbanova, et al.
Pubblicazione: (2024)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’. Authors' Reply
di: Christian Labenz, et al.
Pubblicazione: (2026)

Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing? Authors' Reply
di: Yewan Park, et al.
Pubblicazione: (2024)

Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients with Inflammatory Bowel Disease. Author's Reply
di: A. B. Fons, et al.
Pubblicazione: (2026)